FDA grants orphan-drug status to Erytech's leukemia drug

Graspa, Erytech Pharma's drug candidate for acute lymphoblastic leukemia, received orphan-drug designation from the FDA. The drug is a novel L-asparaginase formulation packed in red blood cells to make it safer. Erytech is considering starting clinical trials of the drug in the U.S., CEO Yann Godfrin said.